{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-029619","form_type":"8-K","ticker":"IDYA","cik":"0001676725","company_name":"IDEAYA Biosciences, Inc.","filed_at":"2024-03-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.079492+00:00","generated_at":"2026-06-04T23:06:27.071600+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"IDEAYA Enters Clinical Collaboration with Merck to Evaluate IDE161 + KEYTRUDA in Endometrial Cancer","bullets":["Phase 1 trial will test IDE161 (PARG inhibitor) + KEYTRUDA in MSI-high and MSS endometrial cancer.","Merck provides KEYTRUDA at no cost; IDEAYA sponsors the trial and pays study costs.","Each party retains full commercial rights to its own compound as monotherapy or combination.","IDE161 has FDA Fast-Track designation for BRCA1/2 ovarian and breast cancers."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-029619","json":"https://secwatch.observer/filing/0000950170-24-029619.json","markdown":"https://secwatch.observer/filing/0000950170-24-029619.md","text":"https://secwatch.observer/filing/0000950170-24-029619.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1676725/000095017024029619/0000950170-24-029619-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1676725/000095017024029619/idya-20240308.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T23:06:27.071600+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}